

Kazuhito Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6505627/publications.pdf>

Version: 2024-02-01

24
papers

2,165
citations

840776

11
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

2514
citing authors

#	ARTICLE	IF	CITATIONS
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
2	Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1157-1163.	1.6	309
3	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
4	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	1.6	86
5	Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Cancer Science</i> , 2008, 99, 179-184.	3.9	36
6	Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. <i>International Journal of Hematology</i> , 2019, 109, 426-439.	1.6	29
7	Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 2426-2435.	3.9	26
8	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 2845-2854.	3.9	24
9	High-dose CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. <i>Cancer Science</i> , 2018, 109, 2830-2840.	3.9	14
10	Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1265-1273.	1.3	14
11	Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. <i>Cancer Science</i> , 2020, 111, 3714-3725.	3.9	13
12	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	6.2	12
13	Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 29-38.	1.3	10
14	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. <i>Blood Advances</i> , 2021, 5, 984-993.	5.2	9
15	Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. <i>Cancer Science</i> , 2021, 112, 331-338.	3.9	8
16	Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4694.	4.1	8
17	Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. <i>Cancer Science</i> , 2021, 112, 2405-2415.	3.9	7
18	Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 70-77.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Japanese Journal of Clinical Oncology, 2020, 50, 1395-1402.	1.3	5
20	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. Blood, 2021, 138, 4457-4457.	1.4	4
21	Râ€CHOPâ€14 versus Râ€CHOPâ€14/CHASER for upfront autologous transplantation in diffuse large Bâ€cell lymphoma: JCOG0908 study. Cancer Science, 2020, 111, 3770-3779.	3.9	3
22	Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01. Blood, 2021, 138, 4464-4464.	1.4	1
23	Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. Japanese Journal of Clinical Oncology, 2022, , .	1.3	1
24	Differences in the approaches of cancer specialists toward adolescent and young adult cancer care. Pediatrics International, 2022, 64, .	0.5	1